智通财经APP获悉，多家美国当地媒体报道称，美国总统唐纳德·特朗普预计将推动把大麻重新归类 为"危害性较低的药物"，这一最新的市场动态无疑直接推动美国大麻类生产商股票周五在美股盘前交易 中大幅上涨。涨幅居前的包括：Tilray Brands(TLRY.US)盘前大涨超30%，Canopy Growth(CGC.US)涨 23%，Aurora Cannabis(ACB.US)涨20%，SNDL(SNDL.US)涨14%，Cronos Group(CRON.US)涨12%。 根据媒体报道，特朗普正在考虑将大麻从"附表I"(Schedule I)——该类别表示无医疗用途且具有高滥用 潜力——大幅度调整至"附表III"——这是一类依赖性与成瘾性潜力较低的物质类别。 据报道，特朗普当地时间周四早些时候与美国众议院议长迈克·约翰逊、特朗普亲自提名的卫生与公众 服务部(HHS)部长小罗伯特·F·肯尼迪、医疗保险和医疗补助服务中心(CMS)署长梅赫梅特·奥兹，以及数 位大麻行业高管通话，讨论该事项。 不过报道称，联系到的一名白宫高级官员表示，特朗普本人尚未给出最终的行政决定。 附表III药物具有已被普遍接受的医疗用途，但仍存 ...

Tilray Brands stock price has rebounded in the past three days, and chances are that the surge will accelerate as a new catalyst emerges. TLRY rose to $8.43, a few days after the company completed its... ...

Group 1 - Cannabis stocks experienced significant gains, with Tilray Brands surging over 28% and Canopy Growth jumping 23% in premarket trading [1] - Innovative Industrial Properties, a cannabis facility operator, also saw an increase of more than 6% [1] - The surge in cannabis stocks was attributed to reports of President Donald Trump planning to ease federal restrictions on marijuana [1] Group 2 - Trump is expected to instruct agencies to reclassify marijuana as a Schedule III drug, which would alter tax regulations for cannabis companies and promote investment [2] - The reclassification would move marijuana from a category that includes heroin to a lower tier with less dangerous drugs, such as steroids and Tylenol with codeine, and is anticipated to occur early next year [2] - This change in classification was previously suggested by Trump in August, highlighting ongoing discussions about marijuana's legal status [3] Group 3 - Despite broader acceptance of cannabis, pot stocks have faced challenges since many went public approximately seven years ago, with Tilray shares down 36% prior to the recent surge [3]

U.S. stock futures swung between gains and losses on Friday after Thursday’s mixed close. Futures of major benchmark indices were mixed.Thursday experienced a rotation out of expensive tech names, which helped U.S. stocks settle mostly higher, with the Dow Jones surging over 600 points. Overall risk appetite remained resilient following the Federal Reserve's third consecutive interest-rate cut delivered a day earlier. Meanwhile, President Donald Trump signed a sweeping executive order aimed at creating a si ...

Core Viewpoint - cbdMD Inc. has regained full compliance with NYSE American listing standards, resulting in a significant increase in its stock price by 54.64% in after-hours trading, reaching $0.98 from a previous close of $0.63 [1][2]. Group 1: Compliance and Listing Status - The NYSE American removed cbdMD's ".BC" noncompliant issuer label, indicating that deficiencies related to shareholders' equity and net loss requirements have been resolved [2]. - The company remains subject to NYSE American's continued listing monitoring procedures, emphasizing its commitment to strong financial discipline and governance [3]. Group 2: Financial Strategy and Achievements - The CEO of cbdMD highlighted that regaining the NYSE American listing is a critical achievement, reflecting efforts to strengthen the company's balance sheet through actions such as the Series A preferred share conversion in May and a capital raise in September [4]. - The company has a market capitalization of $5.58 million and has experienced an 80.94% decline in stock price year to date, with a 52-week trading range of $0.47 to $6.54 [5]. Group 3: Trading Metrics - The stock is currently experiencing long-term consolidation with medium and short-term upward movement, as indicated by Benzinga's Edge Stock Rankings [5].

Core Insights - Tilray Brands, Inc. has launched Amped Live Resin Liquid Diamond 1g 510 cartridges, marking Redecan's first live resin-liquid diamond line, featuring strains Space Age CK and Blueberry DNTS [1][10] - The Amped product line is formulated with 80% Legit Live Resin and 20% Liquid Diamonds, aiming to enhance flavor intensity while maintaining the natural profile of the cannabis plant [2] - The Canadian cannabis market is experiencing growth in live resin vapes, with a reported 6.3% category growth over the past six months, and the timing of this launch aligns with peak vape basket penetration during winter months [4] Product Development - Redecan utilized insights from budtender focus groups to refine the taste, comfort, and design of the Amped cartridges, ensuring a natural flavor profile and improved hardware [5] - The cartridges are designed with a TrueDraw Ceramic core for a smooth draw and to prevent clogs, tailored for premium extractions [3] Market Position - Redecan is recognized as a leading cannabis brand in Canada, known for its quality and innovation across various product lines, including flower, pre-rolls, and vapes [6] - The Amped Live Resin Liquid Diamond cartridges are currently available in Ontario and Alberta, with plans for national distribution in early 2026 [5]

Tilray Brands Inc (NASDAQ:TLRY) experiences a significant stock price recovery, surging over 12% after a challenging period.The company underwent a 1-for-10 reverse stock split, reducing its float and potentially contributing to recent stock price movements.Tilray's market capitalization stands at approximately $924.94 million, with a year of high volatility, indicating the dynamic nature of the cannabis industry.Tilray Brands Inc (NASDAQ:TLRY) is a prominent player in the cannabis industry, known for its p ...

We recently published Small But Savage: 10 Stocks Delivering Outsized Gains. Tilray Brands, Inc. (NASDAQ:TLRY) is one of the best performers on Tuesday. Tilray Brands bounced back by 12.36 percent on Tuesday to close at $8.09 apiece as investor optimism was bolstered by the submission of a new Senate bill, which aims to legalize home cultivation of marijuana in Florida. On Friday, Sen. Carlos Smith filed the legislation seeking to permit qualified patients aged 21 and above to cultivate up to six floweri ...

Group 1 - Tilray's stock price has significantly declined from a high of $23.15 on October 9 to $7.20 currently [1] - The stock price drop may continue to accelerate in the upcoming weeks [1] - A death cross pattern is approaching, indicating potential further declines in stock price [1]

Core Viewpoint - Tilray Brands is a leading company in the cannabis industry but has faced significant challenges over the past five years, leading to poor investment performance. Despite a recent stock price increase of 90% over six months, the initiation of a reverse stock split raises concerns about its future prospects [1][3]. Company Performance - Tilray's stock price rose due to catalysts such as potential cannabis legalization in the U.S. and an unexpected profit reported in the first quarter of fiscal year 2026 [5][6]. - The company implemented a 1-for-10 reverse stock split to avoid delisting from the Nasdaq, indicating underlying performance issues [3]. Market Conditions - The cannabis market has been plagued by regulatory challenges, and the recent momentum towards legalization remains speculative. Actual legal changes have included restrictions that negatively impact Tilray [7][8]. - Organic revenue growth for Tilray has been inconsistent, with net losses being common, reflecting ongoing doubts about the cannabis industry's viability in North America and beyond [8]. Future Outlook - The outlook for Tilray suggests it may continue to be a poor investment choice over the next five years, with recommendations to avoid the stock [9].